This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: https://orca.cardiff.ac.uk/id/eprint/118502/

This is the author’s version of a work that was submitted to / accepted for publication.

Citation for final published version:

Basu, B., Krebs, M. G., Sundar, R., Wilson, R. H., Spicer, J., Jones, R., Brada, M., Talbot, D. C., Steele, N., Ingles Garces, A. H., Brugger, W., Harrington, E. A., Evans, J., Hall, E., Tovey, H., de Oliveira, F. M., Carreira, S., Swales, K., Ruddle, R., Raynaud, F. I., Purchase, B., Dawes, J. C., Parmar, M., Turner, A. J., Tunariu, N., Banerjee, S., de Bono, J. S. and Banerji, U. 2018. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology 29 (9), pp. 1918-1925. 10.1093/annonc/mdy245 file

Publishers page: http://dx.doi.org/10.1093/annonc/mdy245

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

B. Basu1†, M. G. Krebs2†, R. Sundar3,4†, R. H. Wilson5, J. Spicer5, R. Jones5, M. Brada8, D. C. Talbot9, N. Steele10, A. H. Ingles Garces3, W. Brugger11, E. A. Harrington11, J. Evans10, E. Hall12, H. Tovey12, F. M. de Oliveira13, S. Carreira13, K. Swales14, R. Ruddle3,4†, F. I. Raynaud3,4†, B. Purchase3, J. C. Dawes3, M. Parmar3, A. J. Turner6, N. Tunariu3, S. Banerjee15, J. S. de Bono3,13,14* & U. Banerji3,13,14*

1Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge; 2Manchester Academic Health Science Centre, The University of Manchester and The Christie NHS Foundation Trust, Manchester; 3Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, London, UK; 4Department of Haematology-Oncology, National University Health System, Singapore; 5Centre for Cancer Research and Cell Biology, Queen’s University Belfast and Belfast City Hospital, Belfast; 6School of Cancer and Pharmaceutical Sciences, King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, London; 7Cardiff University and Velindre Cancer Centre, Cardiff; 8University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, Wirral; 9Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford; 10University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow; 11Oncology, IMED Biotech Unit AstraZeneca, Cambridge; 12Clinical Trials and Statistics Unit, The Institute of Cancer Research, London; 13Division of Clinical Studies, The Institute of Cancer Research, London; 14Division of Cancer Therapeutics, The Institute of Cancer Research, London; 15Department of Gynae-Oncology, The Royal Marsden, London, UK

*Correspondence to: Prof Udaí Banerji, NIHR Professor of Molecular Cancer Pharmacology & Honorary Consultant in Medical Oncology, Drug Development Unit, Sycamore House, The Institute of Cancer Research and The Royal Marsden, Downs Road, London SM2 5PT, UK Tel: +44-20-8661-3984; Fax: +44-20-8642-7979; E-mail: udaibanerji@icr.ac.uk

†These three authors are joint first authors.

Note: This study was previously presented as a poster at the ASCO Annual Meeting, June 2017; as an oral presentation at the TAT Congress, March 2017; as a poster at the 17th World Conference on Lung Cancer, Dec 2016; as an oral presentation at the ESMO Meeting, October 2016; as an oral poster at the AACR Annual Meeting, April 2015; as a poster at the ACP Annual Meeting, June 2014; as an oral presentation at the TAT Congress, March 2014; and as an oral presentation at the Targeted Anticancer Therapies Congress, March 2014. Pharmacodynamic data of five patients (not all patients) with HGSOC have been used in a previous publication [Wong Te Fong AC et al, Oncotarget 2017, 8(69): 113874-84].

Background: We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients.

Patients and methods: In dose escalation, weekly paclitaxel (80 mg/m²) was given 6/7 weeks in combination with two intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule A, vistusertib dosed bd for 3 consecutive days per week (3/7 days) and schedule B, vistusertib dosed bd for 2 consecutive days per week (2/7 days). After establishing a recommended phase II dose (RP2D), expansion cohorts in high-grade serous ovarian cancer (HGSOC) and squamous non-small-cell lung cancer (SqNSCLC) were explored in 25 and 40 patients, respectively.

Results: The dose-escalation arms comprised 22 patients with advanced solid tumours. The dose-limiting toxicities were fatigue and mucositis in schedule A and rash in schedule B. On the basis of toxicity and pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, the RP2D was established as 80 mg/m² paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks. In the HGSOC expansion, RECIST and GCIG CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively, with median progression-free survival (mPFS) of 5.8 months (95% CI: 3.28–18.54). The RP2D was not well tolerated in the SqNSCLC expansion, but toxicities were manageable after the daily vistusertib dose was reduced to 25 mg bd for the following 23 patients. The RECIST response rate in this group was 8/23 (35%), and the mPFS was 5.8 months (95% CI: 2.76–21.25).
**Introduction**

We have previously studied cancer cells isolated from serous effusions and shown raised p-S6K to be associated with chemoresistance and poor clinical outcome in ovarian and lung cancers, respectively [1, 2]. This led us to hypothesise that inhibition of m-TOR signalling, in combination with chemotherapy, could improve treatment outcomes in these tumour types.

Analogues of rapamycin such as everolimus have been recognised to inhibit only m-TORC1 and not m-TORC2 in the m-TOR complex [3]. The dual m-TORC1/2 inhibitor vistusertib (AZD2014) has a short half-life, giving greater flexibility for intermittent dosing schedules [4, 5]. Weekly paclitaxel was chosen as the chemotherapy backbone, as it is often used to treat advanced ovarian cancer. Pre-clinical studies of vistusertib and paclitaxel revealed an additive effect on growth in vitro and in vivo, with the combination showing increased apoptosis and metabolic effects consistent with the mechanism of action of vistusertib [6].

Here, we report the results of the TAX-TORC study, a phase IB dose-escalation study, with a pre-planned dose-expansion cohort in HGSOC and an additional expansion cohort in sqNSCLC (supplementary Figure S1, available at Annals of Oncology online).

**Patients and methods**

**Conduct of the study**

The academic sponsors of this study were The Institute of Cancer Research and The Royal Marsden (CCR3667), and the trial was reviewed by a central research ethics committee (REC ref: 13/LO/0066). The study was funded by AstraZeneca. Nine Experimental Cancer Medicine Centres across the UK participated in this study. All patients were treated after obtaining written, informed consent. Cancer Research UK trial number: CRUKD/12/013.

**Inclusion/exclusion criteria:** Inclusion criteria in the dose-escalation arm included an ECOG performance status of 0 or 1. Haematological and biochemistry criteria were standard for phase I studies, and details are available in the supplementary data, available at Annals of Oncology online.

**Treatment**

The dose of paclitaxel administered was 80 mg/m² once weekly for 6/7 weeks in a 7-week cycle. In the first week of the dose-escalation cohorts, patients received only paclitaxel on C1D1, then vistusertib on C1D3 to allow for PK and PD samplings. Patients then received weekly paclitaxel (on days 8, 15, 22, 29, and 36) with vistusertib, also starting on days 8, 15, 22, 29, and 36, given orally twice daily either for three consecutive days per week (schedule A: 3/7 days, 6/7 weeks) or two consecutive days per week (schedule B: 2/7 days, 6/7 weeks). In the dose expansion, schedule A was taken forward with patients dosing with vistusertib weekly on days 1–3 for 6 weeks of a 7-week cycle.

**Evaluation of toxicity**

NCI-CTCAE V4.0 was used to assess toxicity.

**Evaluation of response**

RECIST v1.1 was used to assess tumour response supported by GCIG CA125 response in patients with HGSOC. Response was assessed at the end of every 7-week cycle.

**Pharmacokinetic and pharmacodynamic evaluations**

Pharmacokinetic (PK) sampling was carried out for all patients in the dose-escalation arm for 24 h on C1D1 (paclitaxel alone), C1D3 (vistusertib alone), and on C1D1 (combination of paclitaxel and vistusertib). PD sampling was carried out for all patients in the dose-escalation arm. Sampling for PD assays was carried out on the same days as PK sampling. Phosphorylation of AKTSer473 (Ser473 p-AKT) was quantified in platelet-rich plasma (PRP) (for detailed methods, see supplementary data, available at Annals of Oncology online) [7].

**Sequencing**

DNA was extracted from formalin-fixed and paraffin-embedded (FFPE) tumour blocks. In addition, circulating free DNA (cfDNA) when collected at baseline, at the end of cycle 1 and, where possible, at progression, was extracted from 4 to 8 mL of plasma. Sequencing libraries were constructed using a customised Generead DNAseq Mix-n-Match v2 panel (Qiagen) covering 4841 amplicons (310, 077 bp) across 67 genes. Libraries were run using the MiSeq Sequencer (Illumina); sequence alignment and mutation calling were performed.

**Methods—statistical analysis**

The data cut-off for this article was 1 October 2017. Demographics were analysed by descriptive statistics. Safety was assessed in all enrolled patients. Patients considered not assessable for response had no post-baseline CT scan. The number of patients required for the dose-escalation phase was dependent on toxicities observed as the trial progressed. No formal power calculations were done.

Progression-free survival was estimated by the Kaplan–Meier method, beginning on the day of the first dose (C1D1) and continuing until disease progression. Patients who came off study for reasons other than disease progression (clinical or RECIST) were censored. This study is registered with ClinicalTrials.gov, identifier: NCT02193633.
Results

Dose-escalation cohort

Toxicity. Twenty-two patients were recruited to the dose-escalation cohort. The most common tumours were ovarian and lung cancers (supplementary Table S1, available at Annals of Oncology online). In the dose-escalation phase, vistusertib was tested at 25 mg, 50 mg, and 75 mg bd 3/7 days, 6/7 weeks (schedule A) with no dose limiting toxicities (DLTs) in the 25 mg or 50 mg groups. Two of the three patients in the 75 mg group experienced DLTs of fatigue and mucositis. Vistusertib was then tested at 50 mg and 75 mg bd 2/7 days (schedule B) with no DLTs. However, two of the three patients taking 100 mg bd 2/7 days experienced DLTs of rash (supplementary Figure S2, available at Annals of Oncology online). The maximally tolerated dose (MTD) of schedule A was, thus, 80 mg/m$^2$ weekly paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks in a 7-week cycle, with dosing starting concurrently on day 1 of each week. The MTD of schedule B was 80 mg/m$^2$ weekly paclitaxel with 75 mg vistusertib bd 2/7 days for 6/7 weeks in a 7-week cycle, with dosing starting concurrently on day 1 of each week. The most common toxicities across both schedules were predominantly grade 1–2 fatigue, nausea, anaemia, and diarrhoea (Table 1), which are similar to that seen with weekly paclitaxel administration.

Pharmacokinetics. In all schedules tested, the PK of paclitaxel alone or in combination with vistusertib was similar (Table 2). The PK of vistusertib alone or vistusertib in combination with paclitaxel in both schedules was comparable with previous single agent studies [5] (data not shown). The areas under the curve (AUC) versus dose of vistusertib was approximately dose proportional (supplementary Figure S3, available at Annals of Oncology online). Altogether, these suggest that there is no drug-drug PK interaction on drug exposure for either paclitaxel or vistusertib in combination compared with either agent administered alone.

Pharmacodynamics. At the recommended phase II dose (RP2D) level of 50 mg bd of vistusertib and 80 mg/m$^2$ of paclitaxel, there was a statistically non-significant increase in levels of Ser$^{473}$p-AKT at 4 h following 80 mg/m$^2$ paclitaxel (1.4 fold; $P = 0.14$). Vistusertib (50 mg bd 3/7) in addition to paclitaxel produced a reduction in Ser$^{473}$p-AKT at 4 h post-vistusertib to 53% of predose levels ($P = 0.0495$). This was 62% lower than the corresponding time-point following paclitaxel alone, suggesting that, at the RP2D of the combination, there is a significant reduction in p-AKT levels in normal tissue compared with baseline (Figure 1).

RP2D. In combination with weekly paclitaxel administered at 80 mg/m$^2$ once weekly, the MTD of vistusertib was 50 mg bd (3/7 days) (schedule A) or 75 mg bd (2/7 days) (schedule B). Both doses had acceptable PK and PD profiles and would be acceptable as per the pharmacological audit trail [8]. Weekly vistusertib 50 mg bd 3 days on/4 days off combined with weekly paclitaxel

| Adverse event            | Escalation 3d on, 4d off | Escalation 2d on, 5d off | Total |
|--------------------------|--------------------------|--------------------------|-------|
|                          | 25 mg ($N = 3$)          | 50 mg ($N = 6$)          | 75 mg ($N = 3$) |
|                          | Grades 1–2 | Grades 3–4 | Grades 1–2 | Grades 3–4 | Grades 1–2 | Grades 3–4 | Grades 1–2 | Grades 3–4 | Grades 1–2 | Grades 3–4 | Grades 1–2 | Grades 3–4 | Grades 1–2 | Grades 3–4 | Grades 1–2 | Grades 3–4 |
| Fatigue                  | 3 0 5 0 | 0 3 1 0 | 1 2 1 1 | 1 2 1 1 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 |
| Nausea                   | 3 0 4 0 | 0 0 0 0 | 4 0 2 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 |
| Anaemia                  | 2 0 4 0 | 0 2 0 0 | 2 0 2 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 |
| Diarrhoea                | 1 0 3 1 | 1 1 1 1 | 3 0 3 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 |
| Peripheral sensory neuropathy | 1 0 2 0 | 0 1 0 0 | 3 0 1 2 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 |
| Skin rash                | 1 0 1 0 | 1 0 1 0 | 3 0 1 2 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 | 1 0 2 0 |
| Alopecia                 | 1 0 4 0 | 2 0 2 0 | 4 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 |
| Dysgeusia                | 0 0 3 0 | 1 0 1 0 | 4 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 |
| Mucositis                | 1 0 2 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 |
| Neutropenia              | 0 0 2 1 | 1 0 2 1 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 |
| Dyspepsia/gastric reflux | 1 0 3 0 | 0 0 0 0 | 1 0 2 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 |
| Hypophosphataemia        | 1 0 1 0 | 0 3 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 | 0 0 0 0 |
| Pain                     | 0 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 | 1 0 1 0 |
| Paronychia               | 0 0 3 0 | 0 0 0 0 | 1 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 | 0 0 1 0 |

All drug-related events (possibly, probably and, definitely related) seen in more than 20% of patients in the dose-escalation cohorts. A total of 22 patients were treated in the dose escalation. One patient was treated with vistusertib on schedule B at 50 mg instead of 100 mg owing to urgent reporting of two dose-limiting toxicities. The patient did not have grade 3 or 4 toxicity or a dose-limiting toxicity, was evaluable, but has not been represented in the table for simplicity.
80 mg/m² was taken forward as the RP2D based on reduced occurrence of grade 3 fatigue in this cohort.

**Ovarian cancer expansion.** Twenty-seven patients with relapsed/refractory HGSOC were treated at the RP2D. Two patients were replaced as per protocol and were not considered for assessment of response. The median number of previous treatments was three: the majority (26/27; 96%) of patients having received paclitaxel and 3/27 patients (11%) having previously received weekly paclitaxel (supplementary Table S2, available at *Annals of Oncology* online). The RECIST and CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively (Figure 2A). The mPFS was 5.8 months (95% CI: 3.3–18.5).

DNA sequencing (targeted panel of 67 genes) of FFPE tissue revealed that the most common mutation was TP53 detected in 23/25 (92%) patients. There was no correlation between specific mutations and response (Figure 2B).

**Squamous lung cancer expansion.** Following two partial responses in patients with sqNSCLC in the dose-escalation cohort, we conducted a dose expansion in a cohort of 40 patients, starting at the RP2D of 80 mg/m² paclitaxel and 50 mg vistusertib.

### Table 2. Pharmacokinetic profile of vistusertib

| Variable              | Day | 25 mg/80 mg | 50 mg/80 mg | 75 mg/80 mg | 100 mg/80 mg |
|-----------------------|-----|-------------|-------------|-------------|--------------|
|                       |     | Geometric mean | N           | Geometric mean | N           | Geometric mean | N           | Geometric mean | N           |
| AUClast (h*ng/mL)     | 3   | 2090 (1290–3462) | 3           | 2602 (708–11480) | 7           | 7543 (4192–16542) | 9           | 7556 (4188–12884) | 3           |
|                       | 8   | 1054 (181–2785)   | 3           | 2026 (800–6137)   | 7           | 5209 (1576–13363) | 8           | 7347 (4875–13997) | 3           |
| Cmax (ng/mL)          | 3   | 579 (478–785)     | 3           | 840 (462–3580)    | 7           | 1840 (983–2870)  | 9           | 1960 (1180–2670) | 3           |
|                       | 8   | 248 (80–507)      | 3           | 500 (244–764)     | 7           | 1122 (442–1920)  | 8           | 1830 (1490–2420) | 3           |
| HL Lambda_z (h)       | 3   | 3.3 (2.3–4.2)     | 3           | 1.8 (0.8–3.2)     | 6           | 2.7 (1.2–5.9)    | 8           | 3.0 (2.5–3.3)    | 3           |
|                       | 8   | 3.5 (1.9–6.1)     | 3           | 2.2 (1.7–2.9)     | 6           | 3.1 (1.7–7.9)    | 8           | 2.8 (1.2–5.3)    | 3           |

The area under the curve (AUC), maximal concentration (Cmax), and half-life (HL) of vistusertib on C1D3 (administered as a single agent) and C1D8 (administered in combination with paclitaxel) across the different dose levels in the dose-escalation cohort.

![Figure 1](image.png)

**Figure 1.** Pharmacodynamic profile of vistusertib at 50 mg bd 3/7. Phosphorylation of AKT (Ser473) in platelet-rich plasma was quantified using MSD electrochemiluminescent immunoassays and normalised to corresponding total AKT values. Baseline values were established prior to the start of treatment. On C1D1, only paclitaxel (80 mg/m²) was administered and a non-significant rise in p-AKT at 4 h following treatment was noted. On C1D4, a single dose of vistusertib was administered and non-significant reduction of p-AKT was seen. On C1D8, the combination of paclitaxel and vistusertib was administered, which caused a significant reduction of p-AKT compared with baseline. Points represent individual patients, orange line represents mean of up to N = 6 patients. Four samples were excluded because of haemolysis, which interfered with the assay (*P<0.05; paired t-test).

---

80 mg/m² was taken forward as the RP2D based on reduced occurrence of grade 3 fatigue in this cohort.

Ovarian cancer expansion. Twenty-seven patients with relapsed/refractory HGSOC were treated at the RP2D. Two patients were replaced as per protocol and were not considered for assessment of response. The median number of previous treatments was three: the majority (26/27; 96%) of patients having received paclitaxel and 3/27 patients (11%) having previously received weekly paclitaxel (supplementary Table S2, available at *Annals of Oncology* online). The RECIST and CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively (Figure 2A). The mPFS was 5.8 months (95% CI: 3.3–18.5). DNA sequencing (targeted panel of 67 genes) of FFPE tissue revealed that the most common mutation was TP53 detected in 23/25 (92%) patients. There was no correlation between specific mutations and response (Figure 2B).
Figure 2. Clinical outcomes of patients in the ovarian cancer expansion treated at the RP2D for ovarian cancer. (A) Waterfall plot of 23/25 patients with ovarian cancer treated at the RP2D for ovarian cancer that were evaluable for response; two patients clinically progressed with bowel obstruction in the first cycle and did not have a repeat CT scan to assess response. A total of 19 of 25 (76%) patients showed a reduction in size of their tumour, with 13/25 (52%) achieving a partial response. (B) Mutations in tumour tissue or plasma of patients compared with clinical response. (C) Spider plots representing percentage change in measured sum of tumour dimensions of individual patients over time (each cycle is 7 weeks).
Figure 3. Clinical outcomes of patients in the squamous NSCLC expansion treated at the R2PD for squamous NSCLC. (A) Waterfall plot of 21/23 patients with sqNSCLC treated at RP2D of the combination; two patients clinically progressed within their first cycle and repeat radiological evaluation was not done. Eighteen of the 23 (78%) patients showed reduction in the size of their tumour with 8/23 (35%) achieving a partial response. (B) Mutations in tumour tissue or plasma of patients compared with clinical response. (C) Spider plots representing percentage change in measured sum of tumour dimensions of individual patients over the time (each cycle is 7 weeks).
Discussion

We report the first study of the combination of weekly paclitaxel with the dual m-TORC1/2 inhibitor, vistusertib, establishing a safe dose and schedule and preliminary evidence of efficacy in HGSOC and SqNSCLC. We chose to investigate the m-TORC1/2 inhibitor in the context of weekly paclitaxel, as this regimen is often used in the setting of platinum-resistant ovarian cancer [9], and taxanes are commonly used in the treatment of platinum-resistant NSCLC (with comparable efficacy between weekly paclitaxel and docetaxel and better tolerability profile) [10, 11].

Toxicities of fatigue, nausea, anaemia, and diarrhoea in this dose-escalation cohort were not dissimilar to previous studies combining m-TOR inhibitors such as everolimus [12], ridaforolimus [13], or the m-TORC1/2 inhibitor, MLN028 [14], with weekly paclitaxel regimens. Hyperglycaemia, which has been commonly reported with m-TOR inhibitors, occurred at a very low incidence in our study [all grades: N = 8 (11%), grade 3/4: N = 1 (1%)]. It was noted that many earlier studies were in breast cancer, where weekly paclitaxel is often used as standard-of-care. Of interest, in our study, patients with heavily pre-treated HGSOC tolerated vistusertib at 50 mg bd 3 days per week in combination with weekly paclitaxel. However, patients with sqNSCLC needed a dose reduction of vistusertib to 25 mg bd 3 days per week. Patients with sqNSCLC often exhibit risk factors and co-morbidities that correlate with poor tolerance of chemotherapy such as hypoxia, a history of smoking, and pulmonary fibrosis [15]. We have previously reported on the increased risk of infections of patients treated with PI3K pathway inhibitors used as part of combination therapy [16]. In our experience, this is the first time that it has been necessary to recommend two separate doses for different tumour types within the same study.

The PK profile of vistusertib was not significantly different from previous reports in single-agent studies [5] and was no different when administered alone or in combination with paclitaxel. The pharmacodynamic profile of vistusertib in PRP showed administration of vistusertib led to abrogation of AKTSer473 phosphorylation, providing proof-of-principle of the desired biological effect of inhibiting the PI3K–Akt-m-TOR pathway.

The clinical outcomes of patients receiving the combination of weekly paclitaxel and vistusertib in this non-randomised phase I expansion were encouraging for the patient groups explored. In the ovarian cohort, the three median lines of previous treatment were: 12% of patients were platinum-refractory, 48% had progressed within 6 months of the last platinum treatment, and 96% had progressed within a year of their last platinum treatment. In this cohort, the RECIST and CA125 response rates were 52% and 64%, respectively, with a progression-free interval of 5.8 months, which is better than historic data reported for the use of weekly paclitaxel therapy [9]. The control chemotherapy arm of a contemporary phase III study studying the addition of bevacizumab to chemotherapy in the setting of 2nd or 3rd line chemotherapy in a platinum-resistant disease state achieved a response rate of 12% and progression-free survival was 3.9 months [17]. The results of the TAX-TORC study have led to a randomised phase II study of weekly paclitaxel *versus* paclitaxel and vistusertib, which is ongoing (ISRCTN16426935) [18].

The standard-of-care of sqNSCLC changed with the introduction of immune checkpoint inhibitors with response rates of ~15% in patient cohorts not selected for PD-L1 expression confirmed by randomised control trials [19]. In the TAX-TORC study, at the tolerated doses of paclitaxel (80 mg/m²/week) and vistusertib (25 mg bd 3/7 days), the response rate and progression-free survival was 35% and 5.8 months, respectively. These data exceed traditional outcomes for the sqNSCLC population beyond first-line therapy and demonstrate potential for benefit and warrant further evaluation. A possible use of this regimen could be in the setting of patients with sqNSCLC who do not have expression of PD-L1 [20].

We attempted to identify biomarkers of response to the combination by studying a panel of 67 genes that were known to be commonly mutated in HGSOC [21] and sqNSCLC [22]. The mutations found in our study were in keeping with those described elsewhere in these tumour types; however, there were no significant differences in mutation profiles of responders and non-responders in this small dataset.

Conclusion

We report a phase I study combining weekly paclitaxel and a dual m-TORC1/2 inhibitor, vistusertib, with expansions in HGSOC and squamous NSCLC, which are both areas of unmet need. The trial showed tolerable schedules in expansion cohorts of over 20 patients. The response rates and progression-free survival in these non-randomised phase I expansions show promise, and randomised phase II studies are recommended to study these combinations further.

Acknowledgements

The authors would like to thank and acknowledge all patients for taking part in this study and their families, as well as the trial’s research nurses, data managers, and trial coordinators.

Funding

This work was supported by AstraZeneca through Cancer Research UK’s Experimental Cancer Medicine Centre (ECMC) Combinations’ Alliance. All sites acknowledge funding from ECMC awards. In addition, The Institute of Cancer Research...
Disclosure

MGK reports a grant from the National Institute for Health Research, during the conduct of the study, and non-financial support from AstraZeneca outside the submitted work; RS reports a grant from the National Medical Research Council, Singapore, during the conduct of this study; JS declares a non-remunerative collaboration with AstraZeneca, outside the submitted work; NS reports non-financial support from AstraZeneca, outside the submitted work; RB and EAH are employees of AstraZeneca and stock-holders; JE declares reimbursement of study costs to his institution from AstraZeneca for other clinical trials; EH reports a grant to ICR from AstraZeneca, outside the submitted work; HT reports a grant to her institution from AstraZeneca during the conduct of this study; KS has been funded on the Cancer Research UK grant, C347/A18077, during the conduct of the study; AJT declares grants and non-financial support from AstraZeneca, during the conduct of the study; SB reports a grant and personal fees from AstraZeneca, outside the submitted work; JdB declares funding from pleural effusions. Oncology 2016; 90(5): 280–288.

References

1. Carden CP, Stewart A, Thavasu P et al. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther 2012; 11(7): 1609–1617.
2. Puglisi M, Stewart A, Thavasu P et al. Characterisation of the phosphati-
dyinositol 3-kinase pathway in non-small cell lung cancer cells isolated from pleural effusions. Oncology 2016; 90(5): 280–288.
3. Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibi-
tion of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26(10): 1603–1610.
4. Pike KG, Malagui K, Hummersone MG et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013; 23(5): 1212–1216.
5. Basu B, Dean E, Puglisi M et al. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC1/2 inhibitor AZD2014. Clin Cancer Res 2015; 21(15): 3412–3419.
6. Wong Te Fong AC, Thavasu P, Gagrica S et al. Evaluation of the combina-
tion of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclit-
taxel in ovarian cancer models. Oncotarget 2017; 8(69): 113874–113884.
7. Blagden S, Olmin A, Josephs D et al. First-in-human study of CHS132799, an oral class I PI3K inhibitor, studying toxicity, phospho-
kineistics, and pharmacodynamics, in patients with metastatic cancer. Clin Cancer Res 2014; 20(23): 5908–5917.
8. Banerji U, Workman P. Critical parameters in targeted drug develop-
ment: the pharmacological audit trail. Semin Oncol 2016; 43(4): 436–445.
9. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recur-
rent ovarian cancer. Nat Rev Clin Oncol 2010; 7(10): 575–582.
10. Dipasquale M, Murgia V, Veccia A et al. Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre. Anticancer Drugs 2017; 28(6): 654–659.
11. Gao G, Chu H, Zhao L et al. A meta-analysis of paclitaxel-based chemother-
apy administered once every week compared with once every 3
weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer 2012; 76(3): 380–386.
12. Andre F, Campone M, O’Regan R et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28(34): 5110–5115.
13. Sessa C, Tosi D, Viganò L et al. Phase Ib study of weekly mammanian tar-
get of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol 2010; 21(6): 1315–1322.
14. Burris HA, Kurkjian CD, Hart L et al. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2017; 80(2): 261–273.
15. Minami-Shimmyo Y, Ohe Y, Yamamoto S et al. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. J Thorac Oncol 2012; 7(1): 177–182.
16. Rafii S, Sora D, Geuna E et al. Higher risk of infections with PI3K-AKT- mTOR pathway inhibitors in patients with advanced solid tumors on phase I clinical trials. Clin Cancer Res 2015; 21(8): 1869–1876.
17. Pujade-Lauraine E, Hilpert F, Weber B et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32(13): 1302–1308.
18. Banerjee SN, Lewsey L-A, Clamp AR et al. OCTOPUS: a randomised, multi-centre phase II umbrella trial of weekly paclitaxel±/- novel agents in platinum-resistant ovarian cancer—Vistusertib (AZD2014.). J Clin Oncol 2017; 35: TPS5609–TPS5609.
19. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373(2): 123–135.
20. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375(19): 1823–1833.
21. Bell D, Berchuck A, Birrer M et al. Integrated genomic analyses of ovar-
ian carcinoma. Nature 2011; 474(7353): 609–615.
22. Cancer Genome Atlas Research N. Comprehensive genomic character-
ization of squamous cell lung cancers. Nature 2012; 489(7417): 519–525.